共 50 条
- [1] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive ChemotherapyBLOOD, 2020, 136Short, Nicholas J.Sedarati, FarhadZhao, DanTsukurov, OlgaFriedlander, SharonFaller, Douglas V.
- [2] Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II StudyBLOOD, 2021, 138Short, Nicholas J.Montalban-Bravo, GuillermoAlvarado, YesidKonopleva, MarinaJabbour, Elias J.Garcia-Manero, GuillermoYilmaz, MusaJain, NitinBorthakur, GautamDiNardo, Courtney D.Daver, NavalIssa, Ghayas C.Ohanian, MaroPemmaraju, NaveenSasaki, KojiMaiti, AbhishekChien, Kelly S.Ravandi, FarhadKadia, Tapan M.Andreeff, MichaelMuftuoglu, MuharremDelumpa, RicardoBose, PrithvirajPierce, Sherry A.Waller, LourdesBanks, GlendaKantarjian, HagopCortes, Jorge E.
- [3] PEVONEDISTAT (P), VENETOCLAX (V) AND AZACITIDINE (A) VERSUS V plus A IN ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: A RANDOMIZED, PHASE 2 TRIAL (NCT04266795)HAEMATOLOGICA, 2021, 106 (10) : 50 - 51Papayannidis, C.Sedarati, F.Zhao, D.Tsukurov, O.Friedlander, S.Faller, D. V.Short, N. J.
- [4] Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction ChemotherapyBLOOD, 2022, 140 : 3333 - 3335Kambhampati, SumanMcMahon, Christine M.Eghtedar, AlirezaPollyea, Daniel A.de Botton, StephanePigneux, ArnaudCherry, MohamadBall, Brian J.Borthakur, GautamCluzeau, ThomasSchiller, Gary J.Hu, BeibeiVolkert, AngelaGausman, Joanie AasenHodgson, GraemeRoth, David A.Warlick, Erica D.Kelly, Michael J.Stein, Eytan
- [5] A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction ChemotherapyBLOOD, 2021, 138Nannis, Gabriel N.Griffiths, Elizabeth A.Savona, Michael R.Odenike, OlatoyosiRoboz, Gail J.O'Connell, Casey L.Dillingham, JacquelineWason, PrieyaZhu, LixiaChan, DannaKeer, Harold N.Oganesian, AramDao, Kim-HienDiNardo, Courtney D.
- [6] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S256Jaddaoui, SamihaBencharef, HanaaAddakiri, SaraDehbi, HindLamchahab, MounaQuessar, AsmaaMadani, AbdellahOukkache, Bouchra
- [7] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S255Zeidan, Amer M.Westermann, JoergKovacsovics, TiborAssouline, SaritSchuh, Andre C.Kim, Hee-JeMacias, Gabriela RodriguezSanford, DavidLuskin, Marlise R.Stein, Eytan M.Malek, KamelLyu, JiayingStegert, MarioEsteve, Jordi
- [8] Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 MutationBLOOD, 2021, 138Stein, Eytan M.DiNardo, Courtney D.Fathi, Amir T.Mims, Alice S.Savona, Michael R.Stein, Anthony S.Stone, Richard M.Winer, Eric S.Seet, Christopher S.Döener, HartmutPollyea, Daniel A.McCloskey, James K.Odenike, OlatoyosiLowenberg, BobOssenkoppele, Gert J.Patel, PraptiRoshal, MikhailFrattini, Mark G.Lersch, FrederikNabhan, SalahAlmon, CarolineSaatcioglu, DuyguZhang, VickieCooper, MichaelKantarjian, HagopTallman, Martin S.
- [10] Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 TrialBLOOD, 2017, 130Stein, Eytan M.DiNardo, Courtney D.Mims, Alice S.Savona, Michael R.Pratz, KeithStein, Anthony S.Fathi, Amir T.Stone, Richard M.Pollyea, Daniel A.Odenike, OlatoyosiLowenberg, BobDohner, HartmutSchiller, Gary J.Gupta, Ira V.Nabhan, SalahZhang, VickieAlmon, CarolineCooper, MichaelTallman, Martin S.